University of Minnesota. Driven to Discover.
The drug cut the incidence of C difficile by 2.4 percentage points—a 71% relative risk reduction.
Short-course therapy led to a favorable outcome in 79% of patients, compared with 80% in long-course patients.
A benefit was found, however, when pelvic infection was defined by strict criteria.
Data from 60 countries reveal a clear geographic distinction in AMR levels.
The association held even in people without prior antibiotic use.
The rate of decline of MRSA bloodstream infections in US hospitals has slowed since 2012.
Prescribing frequency ranges from 19% in Switzerland to 64% in Turkey.
More than 80% of courses for upper respiratory tract infections, cough, and bronchitis exceeded national guidelines.
Among the findings are very high to extremely high levels of resistance to ciprofloxacin in Campylobacter isolates from people.
Altering electronic ordering for urinary tract infection tests was associated with a 45% reduction in urine cultures.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.